ARCTURUS THERAPEUTICS, INC.

Arcturus Therapeutics, Inc. specializes in the research and development of novel vaccine platforms, with a focus on mRNA-based therapeutics for infectious disease prevention. Their technical expertise centers on self-amplifying RNA (saRNA) technology, lipid nanoparticle (LNP) delivery systems, and rapid-response vaccine design for seasonal and pandemic influenza strains. The company leverages proprietary nucleoside modifications and scalable manufacturing processes to enable high-potency, low-dose vaccine candidates, distinguishing itself through accelerated development timelines and enhanced immunogenicity profiles. Their work directly supports public health preparedness by enabling the procurement of pandemic influenza vaccines (PandFlu) and quadrivalent seasonal influenza vaccines (QSFlu), demonstrating deep proficiency in antigen design, preclinical validation, and translational vaccine development. The contractor has delivered critical biotechnology research services to the Department of Health and Human Services, primarily supporting vaccine acquisition and pandemic response initiatives. This relationship reflects a focused alignment with HHS’s mission to secure and deploy next-generation countermeasures against emerging respiratory pathogens. Their engagement suggests a trusted role in supporting federal biodefense and immunization strategy through scientifically rigorous, contractually defined R&D deliverables. Arcturus operates primarily within NAICS 541714, which encompasses biotechnology research focused on therapeutic and prophylactic innovation outside nanobiotechnology. Their market positioning is defined by expertise in mRNA vaccine platforms, placing them at the forefront of next-generation immunization science. They serve the public health biodefense sector with specialized capabilities in rapid-cycle vaccine development and clinical-stage manufacturing readiness. As a privately held entity based in San Diego, California, Arcturus Therapeutics, Inc. maintains a streamlined organizational structure focused on R&D execution. While no federal certifications are listed, their technical track record in vaccine development and direct engagement with HHS underscores their credibility in the federal biotech procurement landscape. Their geographic presence in a major biotech hub enhances access to talent, research institutions, and supply chain infrastructure critical to advanced therapeutic development.